Topic
4 claims checked
Claim:
Genetic variants in the CYP2C19 gene that reduce CYP2C19 enzyme activity can contribute to relatively treatment-resistant depression by reducing the metabolism of some antidepressant medications.
MOSTLY BS
Claim:
Scientific studies report an association between CYP2C19 genetic variants and major depressive disorder, longer depressive episodes, and greater depressive symptom severity.
NOT BS
Claim:
The human enzyme CYP2C19 metabolizes about 10% of commonly prescribed medications, including some antidepressants, proton pump inhibitors, clopidogrel, and voriconazole.
NOT BS
Claim:
The CYP2C19 gene has high genetic variability with 39 possible alleles that influence the rate of medication metabolism.
HARDLY BS